U.S., Oct. 3 -- ClinicalTrials.gov registry received information related to the study (NCT07202611) titled 'DC/NK Cell Therapy' on Jan. 07.
Brief Summary: Primary Outcomes The primary objective of this trial is to test the safety of formulations containing dendritic cells (DCs) and natural killer (NK) cells cultured in vitro. By evaluating the reactions following the administration of autologous dendritic cells via axillary lymph node injection and natural killer cells via intravenous injection, the study aims to determine the safety profile of these trial products for human use.
Secondary Outcomes
To verify the success rate of the cultured cell formulations and assess the cytotoxic capacity of natural killer cells in targeting and killi...